2seventy bio, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-14-2023 03:20 PM Transcript
Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have the TSVT team with us. With us, we have Chip Baird, CFO; as well as Philip Gregory, Chief Scientific Officer. You had an announcement today. So I might turn it over to you guys to talk about that, and then we can jump into Q&A and the programs.
Sure. Thanks, Salveen, and thanks to Goldman Sachs for inviting us to be here today, and we may make forward-looking statements. So we'll also refer you to our Safe Harbor provision. And I encourage you to do your own homework on the stock. So with that out of the way, I did want to comment. We had a press release this morning about our Phase I study in AML. We unfortunately had a Grade 5 serious adverse events, and that was during the DLT period of that patient's treatment. And as a result, per protocol, we put the study on clinical pause. We've notified the FDA as
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |